[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 106, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 50, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 963111, "exercisedValue": 0, "unexercisedValue": 2049802}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 50, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 676166, "exercisedValue": 0, "unexercisedValue": 234059}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 51, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  O'Neil CPA", "title": "Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 58, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 60, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Subhashis  Banerjee M.D.", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.87, "open": 4.05, "dayLow": 3.9, "dayHigh": 4.13, "regularMarketPreviousClose": 3.87, "regularMarketOpen": 4.05, "regularMarketDayLow": 3.9, "regularMarketDayHigh": 4.13, "payoutRatio": 0.0, "forwardPE": -1.5680935, "volume": 144814, "regularMarketVolume": 144814, "averageVolume": 1054058, "averageVolume10days": 183310, "averageDailyVolume10Day": 183310, "bid": 3.99, "ask": 4.09, "bidSize": 1, "askSize": 1, "marketCap": 98915968, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 7.36, "allTimeHigh": 17.31, "allTimeLow": 1.47, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 4.1852, "twoHundredDayAverage": 3.08685, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -12361037, "profitMargins": 0.0, "floatShares": 4572961, "sharesOutstanding": 24544904, "sharesShort": 284944, "sharesShortPriorMonth": 178188, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0116, "heldPercentInsiders": 0.24041, "heldPercentInstitutions": 0.74396, "shortRatio": 0.11, "shortPercentOfFloat": 0.0287, "impliedSharesOutstanding": 24544904, "bookValue": 5.265, "priceToBook": 0.7654322, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -79188000, "trailingEps": -1.24, "forwardEps": -2.57, "enterpriseToEbitda": 0.148, "52WeekChange": -0.04207921, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 4.03, "targetHighPrice": 23.0, "targetLowPrice": 10.0, "targetMeanPrice": 17.0, "targetMedianPrice": 18.0, "recommendationMean": 1.16667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 122968000, "totalCashPerShare": 5.01, "ebitda": -83600000, "totalDebt": 11691000, "quickRatio": 11.138, "currentRatio": 11.649, "totalRevenue": 0, "debtToEquity": 9.047, "revenuePerShare": 0.0, "returnOnAssets": -0.28757, "returnOnEquity": -0.47961, "grossProfits": 0, "freeCashflow": -50343624, "operatingCashflow": -76675000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.24, "epsForward": -2.57, "epsCurrentYear": -3.09, "priceEpsCurrentYear": -1.3042072, "fiftyDayAverageChange": -0.1552, "fiftyDayAverageChangePercent": -0.037083052, "twoHundredDayAverageChange": 0.9431503, "twoHundredDayAverageChangePercent": 0.30553812, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1770424306, "regularMarketTime": 1770411601, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 4.13438, "regularMarketPrice": 4.03, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": -2.9776704, "postMarketPrice": 3.91, "postMarketChange": -0.120000124, "regularMarketChange": 0.16, "regularMarketDayRange": "3.9 - 4.13", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1054058, "fiftyTwoWeekLowChange": 2.5600002, "fiftyTwoWeekLowChangePercent": 1.7414967, "fiftyTwoWeekRange": "1.47 - 7.36", "fiftyTwoWeekHighChange": -3.33, "fiftyTwoWeekHighChangePercent": -0.45244563, "fiftyTwoWeekChangePercent": -4.207921, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]